主动监测前列腺癌系列活检中肿瘤进展特征及其对局灶治疗的启示
本研究纳入1996至2017年加州大学旧金山分校1057例低/中危前列腺癌主动监测患者,评估系列活检中优势肿瘤分级、体积和局灶性的变化。结果显示肿瘤位置相对稳定,分级/体积显著变化主要发生于优势肿瘤;联合诊断与确认活检有助于筛选局灶治疗候选者。
要点
- 主动监测患者系列活检中优势肿瘤位置相对稳定。
- 分级或体积显著变化主要发生在优势肿瘤内。
- 联合诊断与确认活检比单用诊断活检更能筛选局灶治疗候选者。
核心结论
- 系列活检显示早期前列腺癌主动监测患者肿瘤位置相对稳定,分级和/或体积显著变化主要发生于优势肿瘤。
- 联合诊断与确认活检结果有助于更好地筛选局灶治疗患者。
研究设计与样本
- 回顾性队列研究,纳入1996至2017年加州大学旧金山分校主动监测的低/中危前列腺癌男性,共1057例符合标准。
- 中位活检次数为3次(四分位距2-4),196例(18.5%)接受5次或以上活检。
- 评估优势肿瘤活检分级、体积和局灶性随时间的变化。
主要发现
- 确认活检时43%仍为局灶治疗候选者(其中67%适合靶向/象限消融,33%适合半腺消融),20%活检阴性。
- 初始活检为局灶治疗候选者中,11%在确认活检时特征变得较差。
- 基于初始和确认活检均为候选者中,70%在后续活检时仍适合半腺消融。
关键数值与推荐
- 局灶性良好或差由含肿瘤前列腺部位的穿刺针数、侧别和连续性定义(基于病理报告)。
- 候选者定义为局灶性良好、分级分组(GG)≤2且低体积疾病。
- 适合局灶治疗分为有利(GG≤2、局灶性良好且多参数磁共振成像(mpMRI)一致)或不利(局灶性差、高体积疾病或mpMRI不一致)。
临床怎么用
- 对主动监测患者,联合诊断与确认活检可更准确筛选局灶治疗候选者。
- 优势肿瘤位置稳定提示局灶治疗可针对优势肿瘤进行。
局限性
- 回顾性设计。
- mpMRI信息仅在监测活检时获得。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Active surveillance (AS) is a safe and accepted option for managing men with low-risk prostate cancer. Nevertheless, some patients lack confidence in or access to AS. Focal therapy (FT) is a possible alternative to radical treatment for such patients. OBJECTIVE: We evaluated dominant tumor (DT) progression across serial biopsies to determine whether men on AS could be reasonable candidates for FT. DESIGN, SETTING, AND PARTICIPANTS: Men enrolled in AS at University of California, San Francisco between 1996 and 2017 with low/intermediate risk were included. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Changes in biopsy grade, volume, and focality of the DT over time were assessed. Focality (good or poor for FT) was defined by the number of cores, laterality, and contiguity of prostate sites containing tumor (based on pathology reports). Candidates (either for targeted/quadrant ablation or for hemigland ablation) were defined based on good focality, grade group (GG) ≤2, and low-volume disease. Patients were classified as favorable (GG ≤ 2 with good focality and concordant multiparametric magnetic resonance imaging [mpMRI]) or unfavorable (poor focality or high-volume disease or discordant mpMRI) for FT at surveillance biopsies. RESULTS AND LIMITATIONS: A total of 1057 men met the inclusion criteria. The median number of biopsies per patient was three (interquartile range 2-4), and 196 patients (18.5%) underwent five or more biopsies. At confirmatory biopsy, 43% remained candidates for FT (67% for targeted/quadrant ablation and 33% for hemigland ablation) and 20% had a negative biopsy. Of the candidates for FT at initial biopsy, 11% had less favorable characteristics at confirmatory biopsy. Among candidates for FT based on both initial and confirmatory biopsies, 70% remained favorable for hemigland ablation at subsequent biopsies. Limitations include retrospective design and mpMRI information only at surveillance biopsy. CONCLUSIONS: Serial biopsy findings in men with early-stage cancer on AS show that tumor location remains relatively stable and significant changes in grade and/or volume occur largely in the DT. Combined diagnostic and confirmatory biopsy findings help better select patients for FT than the use of the diagnostic biopsy alone. PATIENT SUMMARY: In a large cohort of patients on active surveillance for prostate cancer, we evaluated changes across serial biopsies to identify potential candidates for focal therapy (FT). Our findings showed that the dominant tumor remained stable over time and the majority of men were favorable candidates for FT.
引用
- Fasulo V, Cowan JE, Maggi M, et al. Characteristics of Cancer Progression on Serial Biopsy in Men on Active Surveillance for Early-stage Prostate Cancer: Implications for Focal Therapy. Eur Urol Oncol. 2020. PMID: 33069628. doi:10.1016/j.euo.2020.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。